Comparable stake leader
GLAZER CAPITAL, LLC
SEC ownership of scPharmaceuticals Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001604950.
Disclosed value leader
5AM Partners IV, LLC
Comparable rows
2/4
Latest evidence
30 Sep 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GLAZER CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 4
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
GLAZER CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Sep 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001604950
- Issuer location
- Burlington, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of scPharmaceuticals Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GLAZER CAPITAL, LLC
Disclosed value leader
5AM Partners IV, LLC
Comparable rows
2/4
Latest evidence
30 Sep 2025
13D/G
3/4/5
Lead comparable stake: 4.6%
2 rows are not safely comparable across share classes.
13D/G row: GLAZER CAPITAL, LLC
Quick read
GLAZER CAPITAL, LLC leads the comparable SEC ownership view at 4.6%.
2 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GLAZER CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
GLAZER CAPITAL, LLC
4.6%
KING LUTHER CAPITAL MANAGEMENT CORP
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GLAZER CAPITAL, LLC |
13D/G
|
4.6%
|
$11,829,640
2,474,820 shares
|
$0 | 02 Sep 2025 |
| KING LUTHER CAPITAL MANAGEMENT CORP |
13D/G
Luther King Capital Management Corporation
|
4%
|
$11,982,841
2,128,391 shares
|
-$8,674,586 | 30 Sep 2025 |
| 5AM Partners IV, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$17,475,704
2,734,852 shares
|
— | 06 Oct 2022 |
| ORBIMED ADVISORS LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$1,011,432
252,858 shares
|
— | 13 Aug 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 09 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to scPharmaceuticals Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
5AM Partners IV, LLC
Net 12M change
$0
Latest report
07 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| 5AM Partners IV, LLC | 10%+ Owner | $17,475,704 | Mixed | 06 Oct 2022 | ||
| ORBIMED ADVISORS LLC | 10%+ Owner | $1,011,432 | Filing P/S | 13 Aug 2024 | ||
| Jack A. Khattar | Director | $0 | Mixed | 07 Oct 2025 | ||
| Leonard D. Schaeffer | Director | $0 | Mixed | 07 Oct 2025 | ||
| Rachael Nokes | CFO and Treasurer | $0 | Mixed | 07 Oct 2025 | ||
| John H. Tucker | President and CEO, Director | $0 | Mixed | 07 Oct 2025 | ||
| Sara Bonstein | Director | Mixed | 07 Oct 2025 | |||
| Mette Kirstine Agger | Director | Mixed | 07 Oct 2025 | |||
| Minnie Baylor-Henry | Director | Mixed | 07 Oct 2025 | |||
| Klaus R. Dr Veitinger | Director | Mixed | 07 Oct 2025 | |||
| Frederick M. Hudson | Director | Mixed | 07 Oct 2025 | |||
| William Tober Abraham | Director | Mixed | 07 Oct 2025 |
Recent insider transactions for scPharmaceuticals Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Leonard D. Schaeffer | SCPH | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -43,104 | 0 | 07 Oct 2025 | Held by Schaeffer Holdings LLC | ||
| Leonard D. Schaeffer | SCPH | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -68,796 | 0 | 07 Oct 2025 | Direct | ||
| Leonard D. Schaeffer | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -66,050 | 0 | 07 Oct 2025 | Direct | ||
| Klaus R. Dr Veitinger | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -72,174 | 0 | 07 Oct 2025 | Direct | ||
| William Tober Abraham | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -66,050 | 0 | 07 Oct 2025 | Direct | ||
| Minnie Baylor-Henry | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -84,422 | 0 | 07 Oct 2025 | Direct | ||
| Frederick M. Hudson | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -72,174 | 0 | 07 Oct 2025 | Direct | ||
| Rachael Nokes | SCPH | Common Stock | Disposed to Issuer | -100% | -125,675 | 0 | 07 Oct 2025 | Direct | ||
| Rachael Nokes | SCPH | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -19.5% | -30,386 | 125,675 | 07 Oct 2025 | Direct | ||
| Rachael Nokes | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -207,646 | 0 | 07 Oct 2025 | Direct | ||
| John H. Tucker | SCPH | Common Stock | Disposed to Issuer | -100% | -318,502 | 0 | 07 Oct 2025 | Direct | ||
| John H. Tucker | SCPH | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -27.8% | -122,345 | 318,502 | 07 Oct 2025 | Direct | ||
| John H. Tucker | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,130,174 | 0 | 07 Oct 2025 | Direct | ||
| Mette Kirstine Agger | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -49,750 | 0 | 07 Oct 2025 | Direct | ||
| Sara Bonstein | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -66,050 | 0 | 07 Oct 2025 | Direct | ||
| Jack A. Khattar | SCPH | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -5,000 | 0 | 07 Oct 2025 | Direct | ||
| Jack A. Khattar | SCPH | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -72,174 | 0 | 07 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.